Abstract
Overview
Introduction
Datamonitor expects the global pulmonary arterial hypertension (PAH) market to
grow from $636m in 2004 to just over $2 billion by 2014, as new product and
formulation launches in the US and a healthy late-stage pipeline drive sales
growth. With this increased interest, combined with increased awareness and
R&D activity, treatment for this orphan disease is set to enter a new era
Scope
- Comprehensive analysis of the attractiveness of the PAH market based on
epidemiology, unmet needs, R&D activity and potential revenue
- Analysis of clinical trial data and market potential of the recently
launched PAH specific therapies and compounds in late stage development
- Detailed comparative analysis of all PAH specific compounds in terms of
efficacy, drug delivery, target audience and cost
- In-depth profiles of current treatments, including PAH specific and
non-PAH specific compounds
Highlights
PAH is a rare condition with an estimated 146,000 sufferers across the US, EU
and Japan. However, despite this low patient population, this market has
attracted R&D investment due to the high unmet needs and high treatment values
per patient
Despite low patient numbers, it is estimated that up to 75% of these patients
are not recognized and treated with therapy, creating significant room for
growth in the number of patients treated with PAH therapies over the next
decade
Actelion's Tracleer, the first oral therapy approved by the FDA in 2001, will
come under significant competitive pressure over the next three years. With
approval for Encysive's Thelin expected in March 2006 and Myogen's ambrisentan
expected to launch in 2007, an intense marketing battle is expected as each
company fights for market share
Reasons to Purchase
- Assess the attractiveness of the PAH market for R&D investment and/or
in-licensing activity
- Gain insight into the current challenges and commercial opportunities
associated with this devastating disease
- Access key opinion leader views on the relative merits and weaknesses of
current and future treatments for PAH, and the unmet needs therein
View Cart
